Orgenesis Inc.: M&A transaction — Orgenesis acquires spinal cord injury IP assets from Neurocords for 1.2M shares

Orgenesis Inc.

Acquired IP assets for advanced regenerative therapies for spinal cord injuries from Neurocords, LLC.
Issued 1,200,000 shares of common stock as consideration; shares restricted for 6 months then free-trading.
Transaction closed March 3, 2025; prior licensing agreements terminated and mutual releases executed.
Orgenesis also gets a 3-month option to acquire Rice University option agreement at no additional cost.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Orgenesis Inc. completed an acquisition involving Neurocords, LLC. for 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis.

Action: acquisition
Counterparty: Neurocords, LLC.
Consideration: 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis

Exact text from the filing

Asset Purchase Agreement, in consideration for the purchase of the Assets, the Company will issue to Neurocords or any other person or entity designated in writing by Neurocords 1,200,000 (one million and two hundred thousand) shares of common stock of Orgenesis, free and clear of any trading restrictions after the initial 6-month restricted period, or any other

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001493152-25-009380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.